Study and Monitoring of Early Undifferentiated Arthritis (ESPOIR)

March 22, 2024 updated by: Societe Francaise de Rhumatologie

Etude et Suivi Des POlyarthrites Indifférenciées Récentes

The French Society of Rheumatology initiated a large national multicenter, longitudinal and prospective cohort, ESPOIR, in order to set up databases to allow various investigations on diagnosis, prognostic markers, epidemiology, pathogenesis and medico-economic factors in the field of early arthritis and rheumatoid arthritis.

The primary objective is to set-up a multicentre cohort of early arthritis (less than 6 months) in France that could serve as a database to studies of various natures.

Specific objectives are in the following domains:

  • diagnosis: to help determine among clinical, biological, radiographic and immunogenetics those parameters allowing for the earliest diagnosis classification as possible, in order to target early therapy;
  • prognosis: to identify early those patients at risk of severe disease by investigating among clinical, biological, genetic and sociologic factors;
  • medico-economic: to identify the costs and their determinants at various disease stage;
  • pathologic: to collect a databank of sera, DNA, RNA to allow for studies of transcriptomes and other genomics.

Secondary objectives are twofold:

  • to monitor adverse events, particularly rare drug adverse events, in collaboration with other international studies
  • to allow access to the data collected in this cohort study in order to facilitate new projects submitted to and approved by the scientific committee.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

All patients were referred to each regional center every 6 months during the first 2 years, then every year. Procedures were set up to avoid patients lost to followup as much as possible. At baseline and at each visit, we recorded data for a set of clinical and biological variables recommended for the management of early arthritis. At each visit, rheumatoid arthritis was classified according to the 1987 American College of Rheumatology (ACR) criteria and retrospectively to the 2010 ACR/European League Against Rheumatism (EULAR) criteria.

At each visit, patients completed function and quality-of-life self-administered questionnaires including the Health Assessment Questionnaire-Disability Index (HAQ-DI), Arthritis Impact Measurement Scales version 2 short form, a medico economic questionnaire, and globally assessed disease, pain at rest and pain during motion on a visual analog scale (VAS). Patients underwent radiographs of the hand and wrist (face) and foot (face and oblique). Radiographs were stored in the radiological coordinating center (Brest) and then were evaluated by the van der Heijde-modified Sharp score. Serum, DNA, urine, were collected at baseline. Serum and urine were also obtained at each follow-up visit. They were then sent and stored in adequate and definite conditions in the biological coordinating centre (Paris-Bichat).

Study Type

Observational

Enrollment (Actual)

813

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

A total of 814 patients with early arthritis were included be- tween November 2002 and april 2005.One patient removed his consent form. All the centres were active and each regional centre recruited between 35 and 83 patients.

Description

Inclusion Criteria:

  • patients aged over 18 and under 70
  • clinical diagnosis of rheumatoid arthritis as certain or probable
  • clinical diagnosis of undifferentiated arthritis potentially becoming rheumatoid arthritis
  • at least 2 inflammatory joints since 6 weeks : a swollen joint has to be observed in two articular sites and be present since at least 6 weeks
  • arthritis starting since less than 6 months
  • never prescribed DMARDS, corticoids, except if less than 2 weeks or except intra-articular injection less than 6 weeks before inclusion
  • corticosteroids could be tolerated if prescribed for duration less than 2 weeks in the month before the inclusion with an average dose less than 20 mg per day and stopped two weeks before inclusion

Exclusion Criteria:

  • patients aged less than 18 years or aged more than 70 years
  • pregnant women
  • undifferentiated rheumatism with no potential chance to become rheumatoid arthritis
  • other inflammatory rheumatisms clearly defined

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Remaining in the cohort.
Time Frame: 20 years
Presence of the patient at the visit.
20 years
Prescription of synthetic or biologic disease-modifying antirheumatic drugs (DMARD).
Time Frame: 20 years
Number of patients treated or not.
20 years
Patient disability evaluation.
Time Frame: 20 years
Evaluation by Health Assessment Questionnaire Disability Index (HAQ-DI). The following categories are assessed by the HAQ-DI: dressing and grooming, arising, eating, walking, hygiene, reach, grip, common daily activities. The patients report the amount of difficulty they have in performing some of these activities. Each question asks on a scale ranging from 0 to 3. Increasing scores indicate worse functioning with 0 indicating no functional impairment and 3 indicating complete impairment.
20 years
Change in Disease Activity (levels of activity or remission)
Time Frame: 20 years
  1. Disease Activity Score (DAS28). The DAS28 provides an absolute indication of RA disease activity on a scale of 0.49 to 9.07 A DAS28 value >5.1 corresponds to a high disease activity, A DAS28 value between 3.2 and 5.1 corresponds to a moderate disease activity, A DAS28 value between 2.6 and 3.2 corresponds to a low disease activity, A DAS28 value < 2.6 corresponds to remission.
  2. Physician and patient activity VAS. Scales from 0 to 100. A high value indicates extreme activity.
20 years
Quality of life assessed by EQ-5D-3L/ EUROQOL
Time Frame: 20 years
The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems.The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. The EQ VAS records the respondent's self-rated health (0-100).
20 years
Quality of life assessed by MOS-SF-36/ MOS 36-Item Short-Form Health Survey
Time Frame: 15 years (from baseline to 15 years)
MOS-SF-36/ MOS 36-Item Short-Form Health Survey contains 8 health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides the perceived change in health. Each dimension has a scale (0-100). Low score=poor quality of life.
15 years (from baseline to 15 years)
Quality of life assessed by AIMS2-SF/Arthritis Impact Measurement Scales 2 Short Form
Time Frame: 14 years (from baseline to 14 years)
AIMS2-SF/Arthritis Impact Measurement Scales 2 Short Form contains 26 items : upper-extremity functioning, lower-extremity functioning, affect, symptoms, social interaction, and role. Scores are summed and converted to a range of 0-10. Higher scores=poorer health.
14 years (from baseline to 14 years)
Radiographic damage evaluation
Time Frame: 20 years
Structural joint damage was assessed radiographically and expressed as change in Total Sharp Score (TSS) and its components.The SHS method evaluates, in each hand, 16 areas for erosions and 15 areas for JSN, and, in each foot, 6 areas for erosions and 6 areas for JSN. The erosion score per hand joint can range from 0 to 5. JSN and joint subluxation or luxation are combined in a single score, from 0 to 4. The maximal score for erosion and JSN are 160 and 120, respectively, for the hands and 120 and 48, respectively, for the feet. The maximal total SHS is 448.
20 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Societe Francaise de Rhumatologie

Collaborators

University Hospital, Strasbourg, France
University Hospital, Rouen
University Hospital, Montpellier
University Hospital, Bordeaux
Saint Antoine University Hospital
University Hospital, Brest
Hôpital Cochin
University Hospital, Toulouse
University Hospital, Lille
University Hospital, Tours
Amiens University Hospital
Bicetre Hospital
Pitié-Salpêtrière Hospital
Bichat Hospital

Investigators

  • Principal Investigator: Bernard COMBE, MD, PHD, Montpellier University Hospital rheumatology department

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 13, 2002

Primary Completion (Actual)

April 19, 2005

Study Completion (Estimated)

June 1, 2025

Study Registration Dates

First Submitted

August 31, 2018

First Submitted That Met QC Criteria

September 7, 2018

First Posted (Actual)

September 11, 2018

Study Record Updates

Last Update Posted (Actual)

March 25, 2024

Last Update Submitted That Met QC Criteria

March 22, 2024

Last Verified

March 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • P030717

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Early Rheumatoid Arthritis or Early Undiffentiated Arthritis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe